Tessa Romero
Stock Analyst at JP Morgan
(4.21)
# 508
Out of 4,732 analysts
56
Total ratings
42.86%
Success rate
22.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Initiates: Overweight | $38 | $11.00 | +245.45% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $2.05 | +631.71% | 4 | Nov 5, 2024 | |
| DYN Dyne Therapeutics | Downgrades: Neutral | $43 → $35 | $14.13 | +147.70% | 4 | Oct 24, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.77 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $43.13 | -28.12% | 5 | Oct 14, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $55 → $68 | $37.59 | +80.90% | 5 | Oct 3, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $45.74 | +55.23% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $7.48 | +287.70% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $26.26 | +18.05% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $32.42 | +41.89% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $17.57 | +42.29% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $5.07 | +294.48% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.16 | +13.64% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $38.52 | +42.78% | 2 | Apr 25, 2023 |
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $11.00
Upside: +245.45%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $2.05
Upside: +631.71%
Dyne Therapeutics
Oct 24, 2024
Downgrades: Neutral
Price Target: $43 → $35
Current: $14.13
Upside: +147.70%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.77
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $43.13
Upside: -28.12%
Biohaven
Oct 3, 2024
Maintains: Overweight
Price Target: $55 → $68
Current: $37.59
Upside: +80.90%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $45.74
Upside: +55.23%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $7.48
Upside: +287.70%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $26.26
Upside: +18.05%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $32.42
Upside: +41.89%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $17.57
Upside: +42.29%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $5.07
Upside: +294.48%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.16
Upside: +13.64%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $38.52
Upside: +42.78%